PolyBio Research Foundation

PolyBio has raisd more than $42 million to invest in breakthrough collaborative science. The Foundation has conceptualized and funded more than 54 research projects at leading institutions including Harvard, Yale, UCSF, Mount Sinai, and Stanford and helped fund 6 clinical trials—accelerating the study of infection-associated chronic diseases from root causes to clinical trials.

We founded and coordinate the Long COVID Research Consortium, connecting leading scientists across disciplines from 15+ leading institutions to share data, align methods, and accelerate discovery of diagnostics and treatments for persistent infection. Our scientific collaborations have produced 28 papers published in top journals like Nature, Science Translational Medicine, and Brain, Behavior & Immunity, uncovering how pathogens drive persistent inflammation and neuroimmune dysfunction. All papers are available on our website.

We believe discovery should travel fast. PolyBio has held 4 biannual free online research symposium where the scientists we’ve funded share their research and insights: you can find information on the next symposium on the PolyBio website. PolyBios’s work has been covered in more than 45 articles in outlets including the NYT, Forbes, Bloomberg, USA Today, Wall Street Journal, Atlantic, NPR, Science, Scientific America, and an op-ed in the LA Times by PolyBio co-Founder and President Amy Proal, calling for more clinical trials for Long COVID.